Abstract:Proteolysis targeting chimera (PROTAC) technology, a groundbreaking strategy for degradation of pathogenic proteins by hijacking of the ubiquitin-proteasome-system has become a promising strategy in drug design. However, the real-time monitoring and visualization of protein degradation processes have been long-standing challenges in the realm of drug development. In this research, we sought to amalgamate the highly efficient protein-degrading capabilities of PROTAC technology with the visualization attributes of fluorescent probes, with the potential to pave the path for the design and development of a novel class of visual PROTACs. These novel PROTACs uniquely possess both fluorescence imaging and therapeutic characteristics, all with the goal of enabling real-time observations of protein degradation processes. Our approach involved the utilization of a high ER-targeting fluorescent probe, previously reported in our laboratory, which served as a warhead that specifically binds to the protein of interest (POI). Additionally, a VHL ligand for recruiting E3 ligase and linkers of various lengths were incorporated to synthesize a series of novel ER-inherent fluorescence PROTACs. Among them, compound A3 demonstrated remarkable efficiency in degrading ERα proteins (DC 50 = 0.12 μM) and displaying exceptional anti-proliferative activity against MCF-7 cells (IC 50 = 0.051 μM). Furthermore, it exhibited impressive fluorescence imaging performance, boasting an emission wavelength of up to 582 nm, a Stokes shift of 116 nm, and consistent optical properties. These attributes make it especially suitable for the real-time, in situ tracking of ERα protein degradation processes, thus may serve as a privileged visual theranostic PROTAC for ERα + breast cancer. This study not only broadens the application spectrum of PROTAC technology but also introduces a novel approach for real-time visualization of protein degradation processes, ultimately enhancing the diagnostic and treatment efficacy of PROTACs.

PROTAC Degrader of Estrogen Receptor Α Targeting DNA-Binding Domain in Breast Cancer.

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Development of Stabilized Peptide-Based PROTACs Against Estrogen Receptor Α

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells

Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery

PROTAC: novel degradable approach for different targets to treat breast cancer

Fluorescence theranostic PROTACs for real-time visualization of ERα degradation

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

Abstract 6577: Chemoproteomic evaluation of PROTACs targeting estrogen receptor alpha for ER+ breast cancer

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

ERα-Targeting PROTAC As a Chemical Knockdown Tool to Investigate the Estrogen Receptor Function in Rat Menopausal Arthritis

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Discovery of ERD-12310A As an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor Α (Erα)

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment

Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG